Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study
•Treatment with different monoclonal antibodies (mAbs) has similar effects on frail patients with COVID-19.•Anti-COVID-19 vaccination does not impact mortality in patients treated with mAbs.•Early administration of mAbs improves outcomes.•Early administration of corticosteroids worsens the prognosis...
Saved in:
Published in | International journal of infectious diseases Vol. 131; pp. 155 - 161 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Canada
Elsevier Ltd
01.06.2023
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Treatment with different monoclonal antibodies (mAbs) has similar effects on frail patients with COVID-19.•Anti-COVID-19 vaccination does not impact mortality in patients treated with mAbs.•Early administration of mAbs improves outcomes.•Early administration of corticosteroids worsens the prognosis.•mAb failure predictors are age, hematologic malignancies, and renal insufficiency.
There is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19.
Prospective study including consecutive COVID-19 outpatients referred by primary care physicians for mAb treatment. The outcomes evaluated were 60-day mortality, time to SARS-CoV-2 clearance, need for hospitalization, and O2 therapy.
Among 1026 COVID-19 patients enrolled, 60.2% received casirivamab/imdevimab and 39.8% sotrivimab. Median age was 63 years, 52.4% were males and median time from positive nasopharyngeal swab to mAbs administration was 3 days (interquartile range, 2-5). 78.1% were vaccinated. Overall, the 60-day mortality was 2.14%. No differences in outcomes were observed between the two mAbs used. No difference was observed in mortality between vaccinated and unvaccinated patients (P = 0.925); although, lower rate of hospitalization (P <0.005), less need for O2 therapy (P <0.0001) and reduced nasopharyngeal swab negativity time (P <0.0001) were observed in vaccinated patients. Early administration of mAbs was associated with lower mortality (P <0.007), whereas corticosteroid use worsened prognosis (P <0.004). The independent predictors associated with higher mortality were older age (P <0.0001), presence of active hematologic malignancies (P <0.0001), renal failure (P <0.041), and need for O2 therapy (P <0.001).
This study shows similar effectiveness among mAbs used, regardless of vaccination status and identifies patients with COVID-19 in whom mAbs have poor activity.
[Display omitted] |
---|---|
AbstractList | There is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19.
Prospective study including consecutive COVID-19 outpatients referred by primary care physicians for mAb treatment. The outcomes evaluated were 60-day mortality, time to SARS-CoV-2 clearance, need for hospitalization, and O
therapy.
Among 1026 COVID-19 patients enrolled, 60.2% received casirivamab/imdevimab and 39.8% sotrivimab. Median age was 63 years, 52.4% were males and median time from positive nasopharyngeal swab to mAbs administration was 3 days (interquartile range, 2-5). 78.1% were vaccinated. Overall, the 60-day mortality was 2.14%. No differences in outcomes were observed between the two mAbs used. No difference was observed in mortality between vaccinated and unvaccinated patients (P = 0.925); although, lower rate of hospitalization (P <0.005), less need for O
therapy (P <0.0001) and reduced nasopharyngeal swab negativity time (P <0.0001) were observed in vaccinated patients. Early administration of mAbs was associated with lower mortality (P <0.007), whereas corticosteroid use worsened prognosis (P <0.004). The independent predictors associated with higher mortality were older age (P <0.0001), presence of active hematologic malignancies (P <0.0001), renal failure (P <0.041), and need for O
therapy (P <0.001).
This study shows similar effectiveness among mAbs used, regardless of vaccination status and identifies patients with COVID-19 in whom mAbs have poor activity. OBJECTIVESThere is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19. METHODSProspective study including consecutive COVID-19 outpatients referred by primary care physicians for mAb treatment. The outcomes evaluated were 60-day mortality, time to SARS-CoV-2 clearance, need for hospitalization, and O2 therapy. RESULTSAmong 1026 COVID-19 patients enrolled, 60.2% received casirivamab/imdevimab and 39.8% sotrivimab. Median age was 63 years, 52.4% were males and median time from positive nasopharyngeal swab to mAbs administration was 3 days (interquartile range, 2-5). 78.1% were vaccinated. Overall, the 60-day mortality was 2.14%. No differences in outcomes were observed between the two mAbs used. No difference was observed in mortality between vaccinated and unvaccinated patients (P = 0.925); although, lower rate of hospitalization (P <0.005), less need for O2 therapy (P <0.0001) and reduced nasopharyngeal swab negativity time (P <0.0001) were observed in vaccinated patients. Early administration of mAbs was associated with lower mortality (P <0.007), whereas corticosteroid use worsened prognosis (P <0.004). The independent predictors associated with higher mortality were older age (P <0.0001), presence of active hematologic malignancies (P <0.0001), renal failure (P <0.041), and need for O2 therapy (P <0.001). CONCLUSIONThis study shows similar effectiveness among mAbs used, regardless of vaccination status and identifies patients with COVID-19 in whom mAbs have poor activity. Objectives: There is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19. Methods: Prospective study including consecutive COVID-19 outpatients referred by primary care physicians for mAb treatment. The outcomes evaluated were 60-day mortality, time to SARS-CoV-2 clearance, need for hospitalization, and O2 therapy. Results: Among 1026 COVID-19 patients enrolled, 60.2% received casirivamab/imdevimab and 39.8% sotrivimab. Median age was 63 years, 52.4% were males and median time from positive nasopharyngeal swab to mAbs administration was 3 days (interquartile range, 2-5). 78.1% were vaccinated. Overall, the 60-day mortality was 2.14%. No differences in outcomes were observed between the two mAbs used. No difference was observed in mortality between vaccinated and unvaccinated patients (P = 0.925); although, lower rate of hospitalization (P <0.005), less need for O2 therapy (P <0.0001) and reduced nasopharyngeal swab negativity time (P <0.0001) were observed in vaccinated patients. Early administration of mAbs was associated with lower mortality (P <0.007), whereas corticosteroid use worsened prognosis (P <0.004). The independent predictors associated with higher mortality were older age (P <0.0001), presence of active hematologic malignancies (P <0.0001), renal failure (P <0.041), and need for O2 therapy (P <0.001). Conclusion: This study shows similar effectiveness among mAbs used, regardless of vaccination status and identifies patients with COVID-19 in whom mAbs have poor activity. •Treatment with different monoclonal antibodies (mAbs) has similar effects on frail patients with COVID-19.•Anti-COVID-19 vaccination does not impact mortality in patients treated with mAbs.•Early administration of mAbs improves outcomes.•Early administration of corticosteroids worsens the prognosis.•mAb failure predictors are age, hematologic malignancies, and renal insufficiency. There is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19. Prospective study including consecutive COVID-19 outpatients referred by primary care physicians for mAb treatment. The outcomes evaluated were 60-day mortality, time to SARS-CoV-2 clearance, need for hospitalization, and O2 therapy. Among 1026 COVID-19 patients enrolled, 60.2% received casirivamab/imdevimab and 39.8% sotrivimab. Median age was 63 years, 52.4% were males and median time from positive nasopharyngeal swab to mAbs administration was 3 days (interquartile range, 2-5). 78.1% were vaccinated. Overall, the 60-day mortality was 2.14%. No differences in outcomes were observed between the two mAbs used. No difference was observed in mortality between vaccinated and unvaccinated patients (P = 0.925); although, lower rate of hospitalization (P <0.005), less need for O2 therapy (P <0.0001) and reduced nasopharyngeal swab negativity time (P <0.0001) were observed in vaccinated patients. Early administration of mAbs was associated with lower mortality (P <0.007), whereas corticosteroid use worsened prognosis (P <0.004). The independent predictors associated with higher mortality were older age (P <0.0001), presence of active hematologic malignancies (P <0.0001), renal failure (P <0.041), and need for O2 therapy (P <0.001). This study shows similar effectiveness among mAbs used, regardless of vaccination status and identifies patients with COVID-19 in whom mAbs have poor activity. [Display omitted] |
Author | Salvatore, Teresa Marrone, Aldo Adinolfi, Luigi Elio Feola, Giovanni Sasso, Ferdinando Carlo Marfella, Raffaele Fusco, Raffaele Lettieri, Miriam Coppola, Nicola Loffredo, Giuseppe Cozzolino, Domenico Rinaldi, Luca Villani, Angela Ruocco, Rachele Core, Micol Del Pisaturo, Mariantonietta Sposito, Pellegrino De Lucia Starace, Mario Cirigliano, Giovanna Russo, Antonio De Pascalis, Stefania Nevola, Riccardo |
Author_xml | – sequence: 1 givenname: Riccardo surname: Nevola fullname: Nevola, Riccardo organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 2 givenname: Giovanni surname: Feola fullname: Feola, Giovanni organization: Covid Center-Maddaloni Hospital, Maddaloni, Italy – sequence: 3 givenname: Rachele surname: Ruocco fullname: Ruocco, Rachele organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 4 givenname: Antonio orcidid: 0000-0002-4224-5343 surname: Russo fullname: Russo, Antonio organization: Department of Mental Health and Public Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy – sequence: 5 givenname: Angela orcidid: 0000-0003-2706-578X surname: Villani fullname: Villani, Angela organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 6 givenname: Raffaele surname: Fusco fullname: Fusco, Raffaele organization: Covid Center-Maddaloni Hospital, Maddaloni, Italy – sequence: 7 givenname: Stefania surname: De Pascalis fullname: De Pascalis, Stefania organization: Department of Mental Health and Public Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy – sequence: 8 givenname: Micol Del surname: Core fullname: Core, Micol Del organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 9 givenname: Giovanna surname: Cirigliano fullname: Cirigliano, Giovanna organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 10 givenname: Mariantonietta surname: Pisaturo fullname: Pisaturo, Mariantonietta organization: Department of Mental Health and Public Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy – sequence: 11 givenname: Giuseppe surname: Loffredo fullname: Loffredo, Giuseppe organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 12 givenname: Luca surname: Rinaldi fullname: Rinaldi, Luca organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 13 givenname: Aldo surname: Marrone fullname: Marrone, Aldo organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 14 givenname: Mario surname: Starace fullname: Starace, Mario organization: Department of Mental Health and Public Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy – sequence: 15 givenname: Pellegrino De Lucia surname: Sposito fullname: Sposito, Pellegrino De Lucia organization: Covid Center-Maddaloni Hospital, Maddaloni, Italy – sequence: 16 givenname: Domenico surname: Cozzolino fullname: Cozzolino, Domenico organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 17 givenname: Teresa surname: Salvatore fullname: Salvatore, Teresa organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 18 givenname: Miriam surname: Lettieri fullname: Lettieri, Miriam organization: Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK – sequence: 19 givenname: Raffaele surname: Marfella fullname: Marfella, Raffaele organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 20 givenname: Ferdinando Carlo orcidid: 0000-0002-9142-7848 surname: Sasso fullname: Sasso, Ferdinando Carlo organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy – sequence: 21 givenname: Nicola surname: Coppola fullname: Coppola, Nicola organization: Covid Center-Maddaloni Hospital, Maddaloni, Italy – sequence: 22 givenname: Luigi Elio surname: Adinolfi fullname: Adinolfi, Luigi Elio email: luigielio.adinolfi@unicampania.it organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36944382$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Uctu1DAUjVARfcAPsEBesvHgRyZxEJvR8BqpqBKFbq0b-wYcMvHU9rSaj-FfcTKlYoV0JVvnZV2f8-Jk9CMWxUvOFpzx6k2_cL2zC8GEXLBp2JPijKtaUbnk_CTfBeO0qbk4Lc5j7BljZVWpZ8WprJqylEqcFb-_-JBgcOlAYLQkuPiLdGCSD5H4jtyBMW6EhHam9-M_QBfADWQHyeGYIrl36SdZX91s3lPekBRwFs0ojMnR69XXa7r2N1SQrR-9GfwIw0y13jqMb8mKZNNA730YLIlpbw_Pi6cdDBFfPJwXxfePH76tP9PLq0-b9eqSmrxQogoAlwyMZTVbCs6sbFVpqtp0LRMVlK1SZSV4ppu6YxZMK2xXG9lCWclaGXlRbI651kOvd8FtIRy0B6dnwIcfGkJyZkAtJbZL7IQSZVW2nW0qBRIxhwgoleQ56_Uxaxf87R5j0lsXDQ4DjOj3UYta5Up4w1mWiqPUBB9jwO7xac70VLHu9VSxnirWbJrJ9Oohf99u0T5a_naaBe-OAsw_ducw6GhyRQatC2hSXsn9L_8PiNi6Rw |
CitedBy_id | crossref_primary_10_1002_jmv_29541 crossref_primary_10_1016_j_ijid_2023_06_021 crossref_primary_10_3390_jcm12175691 crossref_primary_10_3389_fimmu_2024_1295029 |
Cites_doi | 10.1002/ajh.26626 10.3390/jcm11206121 10.1093/cid/ciac014 10.1080/08923973.2021.1993894 10.1056/NEJMoa2021436 10.1016/S1473-3099(22)00365-6 10.1056/NEJMoa2108163 10.1159/000512063 10.1056/NEJMoa2107934 10.1016/S1473-3099(22)00320-6 10.1001/jamanetworkopen.2022.38871 10.1038/s41586-022-05053-w 10.1016/S0140-6736(22)00163-5 10.1038/s41586-022-04980-y |
ContentType | Journal Article |
Copyright | 2023 The Authors Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. |
Copyright_xml | – notice: 2023 The Authors – notice: Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 DOA |
DOI | 10.1016/j.ijid.2023.03.030 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health |
EISSN | 1878-3511 |
EndPage | 161 |
ExternalDocumentID | oai_doaj_org_article_33eb5ef282464bfd968a3ee8c32a4831 10_1016_j_ijid_2023_03_030 36944382 S1201971223001108 |
Genre | Journal Article |
GroupedDBID | --- --K .1- .FO .~1 0R~ 0SF 1B1 1P~ 1~. 1~5 29J 3O- 3V. 4.4 457 4G. 53G 5GY 5VS 6I. 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AACTN AAEDW AAFTH AAIKJ AALRI AAQFI AAQXK AARKO AAXUO ABBQC ABFRF ABMAC ABUWG ABVKL ACGFO ADBBV ADEZE ADMUD AEFWE AEKER AENEX AEVXI AEXQZ AFCTW AFKRA AFRHN AFTJW AGEKW AGHFR AGYEJ AHMBA AITUG AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A NCXOZ O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PQQKQ PROAC PSQYO Q2X Q38 QTD R2- RIG ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R ADVLN AFJKZ AKRWK ALIPV CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c466t-8aae50acd0705210d3b84c67cfb026a4b884621d0797f0dacb2df7c3ba46378c3 |
IEDL.DBID | DOA |
ISSN | 1201-9712 |
IngestDate | Fri Oct 04 13:05:43 EDT 2024 Mon Sep 23 08:33:57 EDT 2024 Thu Sep 26 16:10:43 EDT 2024 Sat Sep 28 08:13:25 EDT 2024 Fri Feb 23 02:36:27 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 Monoclonal antibodies Predictors of mortality Vaccination status |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c466t-8aae50acd0705210d3b84c67cfb026a4b884621d0797f0dacb2df7c3ba46378c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-9142-7848 0000-0002-4224-5343 0000-0003-2706-578X |
OpenAccessLink | https://doaj.org/article/33eb5ef282464bfd968a3ee8c32a4831 |
PMID | 36944382 |
PQID | 2789711910 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_33eb5ef282464bfd968a3ee8c32a4831 proquest_miscellaneous_2789711910 crossref_primary_10_1016_j_ijid_2023_03_030 pubmed_primary_36944382 elsevier_sciencedirect_doi_10_1016_j_ijid_2023_03_030 |
PublicationCentury | 2000 |
PublicationDate | June 2023 2023-Jun 2023-06-00 20230601 2023-06-01 |
PublicationDateYYYYMMDD | 2023-06-01 |
PublicationDate_xml | – month: 06 year: 2023 text: June 2023 |
PublicationDecade | 2020 |
PublicationPlace | Canada |
PublicationPlace_xml | – name: Canada |
PublicationTitle | International journal of infectious diseases |
PublicationTitleAlternate | Int J Infect Dis |
PublicationYear | 2023 |
Publisher | Elsevier Ltd Elsevier |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
References | 2022 [accessed 28 December 2022]. Kow, Ramachandram, Hasan (bib0010) 2022; 44 Wang, Guo, Iketani, Nair, Li, Mohri (bib0020) 2022; 608 2022 [accessed 23 March 2023]. European Centre for Disease Prevention and Control. Weekly COVID-19 country overview 2021 [accessed 17 March 2021]. National Institutes of Health. Covid-19 treatment guidelines. Anti-SARS-CoV-2 monoclonal antibodies Cao, Yisimayi, Jian, Song, Xiao, Wang (bib0019) 2022; 608 AIFA. Italian medicine agency. Use Monoclonal Antibodies COVID Horby, Lim (bib0016) 2021; 384 Weinreich, Sivapalasingam, Norton, Ali, Gao, Bhore (bib0009) 2021; 385 Marrone, Nevola, Sellitto, Cozzolino, Romano, Cuomo (bib0004) 2022; 75 Fernandes, Pereira (bib0005) 2022; 9 Centers for Disease Control and Prevention. COVID data tracker: variant proportions Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. 2021;385:1941–50. https://doi.org/10.1056/NEJMoa2107934. Yamasoba, Kosugi, Kimura, Fujita, Uriu, Ito (bib0021) 2022; 22 Blennow, Salmanton-García, Nowak, Itri, Van Doesum, López-García (bib0013) 2022; 97 2023 [accessed 30 March 2023]. Grasselli, Zanella, Carlesso, Florio, Canakoglu, Bellani (bib0014) 2022; 5 National Institutes of Health. Covid-19 treatment guidelines. Antiviral Drug that are approved, authorized, or under evaluation for the treatment of COVID-10 2022 [accessed 6 March 2023]. Calò, Onorato, Pisaturo, Pinto, Alessio, Monari (bib0008) 2022; 10 (bib0012) 2022; 399 Tang, Feng, Ni, Zhang, Liu, Hu (bib0015) 2021; 100 Galiero, Simeon, Loffredo, Caturano, Rinaldi, Vetrano (bib0017) 2022; 11 Watson, Barnsley, Toor, Hogan, Winskill, Ghani (bib0002) 2022; 22 (10.1016/j.ijid.2023.03.030_bib0012) 2022; 399 Horby (10.1016/j.ijid.2023.03.030_bib0016) 2021; 384 10.1016/j.ijid.2023.03.030_bib0006 Blennow (10.1016/j.ijid.2023.03.030_bib0013) 2022; 97 Tang (10.1016/j.ijid.2023.03.030_bib0015) 2021; 100 10.1016/j.ijid.2023.03.030_bib0007 10.1016/j.ijid.2023.03.030_bib0018 Grasselli (10.1016/j.ijid.2023.03.030_bib0014) 2022; 5 Yamasoba (10.1016/j.ijid.2023.03.030_bib0021) 2022; 22 Galiero (10.1016/j.ijid.2023.03.030_bib0017) 2022; 11 Weinreich (10.1016/j.ijid.2023.03.030_bib0009) 2021; 385 Wang (10.1016/j.ijid.2023.03.030_bib0020) 2022; 608 Fernandes (10.1016/j.ijid.2023.03.030_bib0005) 2022; 9 Calò (10.1016/j.ijid.2023.03.030_bib0008) 2022; 10 Kow (10.1016/j.ijid.2023.03.030_bib0010) 2022; 44 Cao (10.1016/j.ijid.2023.03.030_bib0019) 2022; 608 10.1016/j.ijid.2023.03.030_bib0001 10.1016/j.ijid.2023.03.030_bib0003 Watson (10.1016/j.ijid.2023.03.030_bib0002) 2022; 22 Marrone (10.1016/j.ijid.2023.03.030_bib0004) 2022; 75 10.1016/j.ijid.2023.03.030_bib0011 |
References_xml | – volume: 608 start-page: 603 year: 2022 end-page: 608 ident: bib0020 article-title: Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 publication-title: Nature contributor: fullname: Mohri – volume: 385 start-page: e81 year: 2021 ident: bib0009 article-title: REGEN-COV antibody combination and outcomes in outpatients with COVID-19 publication-title: N Engl J Med contributor: fullname: Bhore – volume: 399 start-page: 665 year: 2022 end-page: 676 ident: bib0012 article-title: Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial publication-title: Lancet – volume: 75 start-page: e403 year: 2022 end-page: e409 ident: bib0004 article-title: Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of coronavirus disease 2019 (COVID-19) patients requiring supplemental O2 therapy: a prospective controlled nonrandomized study publication-title: Clin Infect Dis contributor: fullname: Cuomo – volume: 44 start-page: 28 year: 2022 end-page: 34 ident: bib0010 article-title: The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials publication-title: Immunopharmacol Immunotoxicol contributor: fullname: Hasan – volume: 608 start-page: 593 year: 2022 end-page: 602 ident: bib0019 article-title: BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection publication-title: Nature contributor: fullname: Wang – volume: 10 year: 2022 ident: bib0008 article-title: Fatal outcome of COVID-19 relapse in a fully vaccinated patient with non-Hodgkin lymphoma receiving maintenance therapy with the anti-CD20 monoclonal antibody obinutuzumab: a case report publication-title: Vaccines (Basel) contributor: fullname: Monari – volume: 97 start-page: E312 year: 2022 end-page: E317 ident: bib0013 article-title: Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report publication-title: Am J Hematol contributor: fullname: López-García – volume: 9 year: 2022 ident: bib0005 article-title: Frailty in the context of COVID-19 pandemic: a life-threatening condition publication-title: Front Med (Lausanne) contributor: fullname: Pereira – volume: 22 start-page: 1293 year: 2022 end-page: 1302 ident: bib0002 article-title: Global impact of the first year of COVID-19 vaccination: a mathematical modelling study publication-title: Lancet Infect Dis contributor: fullname: Ghani – volume: 22 start-page: 942 year: 2022 end-page: 943 ident: bib0021 article-title: Neutralisation sensitivity of SARS-CoV-2 Omicron subvariants to therapeutic monoclonal antibodies publication-title: Lancet Infect Dis contributor: fullname: Ito – volume: 11 start-page: 6121 year: 2022 ident: bib0017 article-title: Association between renal function at admission and COVID-19 in-hospital mortality in Southern Italy: findings from the prospective multicenter Italian COVOCA study publication-title: J Clin Med contributor: fullname: Vetrano – volume: 100 start-page: 116 year: 2021 end-page: 126 ident: bib0015 article-title: Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial publication-title: Respiration contributor: fullname: Hu – volume: 5 year: 2022 ident: bib0014 article-title: Association of COVID-19 vaccinations with Intensive Care Unit admissions and outcome of critically ill patients with COVID-19 pneumonia in Lombardy, Italy publication-title: JAMA Netw Open contributor: fullname: Bellani – volume: 384 start-page: 693 year: 2021 end-page: 704 ident: bib0016 article-title: Dexamethasone in hospitalized patients with Covid-19 publication-title: N Engl J Med contributor: fullname: Lim – volume: 97 start-page: E312 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0013 article-title: Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report publication-title: Am J Hematol doi: 10.1002/ajh.26626 contributor: fullname: Blennow – volume: 10 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0008 article-title: Fatal outcome of COVID-19 relapse in a fully vaccinated patient with non-Hodgkin lymphoma receiving maintenance therapy with the anti-CD20 monoclonal antibody obinutuzumab: a case report publication-title: Vaccines (Basel) contributor: fullname: Calò – ident: 10.1016/j.ijid.2023.03.030_bib0001 – volume: 11 start-page: 6121 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0017 article-title: Association between renal function at admission and COVID-19 in-hospital mortality in Southern Italy: findings from the prospective multicenter Italian COVOCA study publication-title: J Clin Med doi: 10.3390/jcm11206121 contributor: fullname: Galiero – volume: 75 start-page: e403 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0004 article-title: Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of coronavirus disease 2019 (COVID-19) patients requiring supplemental O2 therapy: a prospective controlled nonrandomized study publication-title: Clin Infect Dis doi: 10.1093/cid/ciac014 contributor: fullname: Marrone – volume: 44 start-page: 28 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0010 article-title: The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials publication-title: Immunopharmacol Immunotoxicol doi: 10.1080/08923973.2021.1993894 contributor: fullname: Kow – volume: 384 start-page: 693 year: 2021 ident: 10.1016/j.ijid.2023.03.030_bib0016 article-title: Dexamethasone in hospitalized patients with Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2021436 contributor: fullname: Horby – volume: 22 start-page: 942 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0021 article-title: Neutralisation sensitivity of SARS-CoV-2 Omicron subvariants to therapeutic monoclonal antibodies publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00365-6 contributor: fullname: Yamasoba – volume: 385 start-page: e81 year: 2021 ident: 10.1016/j.ijid.2023.03.030_bib0009 article-title: REGEN-COV antibody combination and outcomes in outpatients with COVID-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2108163 contributor: fullname: Weinreich – ident: 10.1016/j.ijid.2023.03.030_bib0018 – volume: 100 start-page: 116 year: 2021 ident: 10.1016/j.ijid.2023.03.030_bib0015 article-title: Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial publication-title: Respiration doi: 10.1159/000512063 contributor: fullname: Tang – ident: 10.1016/j.ijid.2023.03.030_bib0011 doi: 10.1056/NEJMoa2107934 – ident: 10.1016/j.ijid.2023.03.030_bib0007 – ident: 10.1016/j.ijid.2023.03.030_bib0006 – volume: 22 start-page: 1293 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0002 article-title: Global impact of the first year of COVID-19 vaccination: a mathematical modelling study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00320-6 contributor: fullname: Watson – ident: 10.1016/j.ijid.2023.03.030_bib0003 – volume: 5 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0014 article-title: Association of COVID-19 vaccinations with Intensive Care Unit admissions and outcome of critically ill patients with COVID-19 pneumonia in Lombardy, Italy publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2022.38871 contributor: fullname: Grasselli – volume: 608 start-page: 603 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0020 article-title: Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 publication-title: Nature doi: 10.1038/s41586-022-05053-w contributor: fullname: Wang – volume: 9 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0005 article-title: Frailty in the context of COVID-19 pandemic: a life-threatening condition publication-title: Front Med (Lausanne) contributor: fullname: Fernandes – volume: 399 start-page: 665 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0012 article-title: Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial publication-title: Lancet doi: 10.1016/S0140-6736(22)00163-5 – volume: 608 start-page: 593 year: 2022 ident: 10.1016/j.ijid.2023.03.030_bib0019 article-title: BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection publication-title: Nature doi: 10.1038/s41586-022-04980-y contributor: fullname: Cao |
SSID | ssj0004668 |
Score | 2.431775 |
Snippet | •Treatment with different monoclonal antibodies (mAbs) has similar effects on frail patients with COVID-19.•Anti-COVID-19 vaccination does not impact mortality... There is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19. Prospective... OBJECTIVESThere is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19.... Objectives: There is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19.... |
SourceID | doaj proquest crossref pubmed elsevier |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | 155 |
SubjectTerms | Aged Antibodies, Monoclonal - therapeutic use Antibodies, Viral COVID-19 Female Frail Elderly Humans Male Middle Aged Monoclonal antibodies Outpatients Predictors of mortality Prospective Studies Risk Factors SARS-CoV-2 Vaccination status |
SummonAdditionalLinks | – databaseName: Elsevier Free Content dbid: IXB link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBelD2MwxtZ9ZV9osLchYluyLe8tzVa6QTZY1pI3oS8Xl2CXNNl_0_-1d5Jc0oftYSQvkU6x8J3vTtL9fibkYy7g40vJkIycCfAGTGeuZBAbLS_BZITBrYHFj-r0THxflasDMh-xMFhWmXx_9OnBW6eWabqb06uumy5ziF1NnUN8C8RnCPhFbk8E8a2O97CREQ4HwgylE3Am1nh1lx2yhRY8EJ1iJfRecAoc_vdi1N9y0BCLTp6QxymJpLM4z6fkwPdH5MEiHZMfkUdxM45GjNEzcrMISTYk3FT3jmI5OU0v2qFDS_9oC-Mg6XShe9fvNbQb3a1pYl-9prhtS-c_z799YXlDQ5U6CIVWUFHHlrNfSzYfzllBwb4Hu8ZEP3SZAesVP9MZhUFrFphaaSC3fU7OTr7-np-y9F4GZuFubpnU2peZtg7cBUT_zHEjha1q2xpY0WlhJCQ1RQ7dTd1mTltTuLa23GhR8Vpa_oIc9kPvXxHKuasRB2FgkKgLqXNufQZLGKely3Q7IZ9GhairSL-hxrq0S4XqU6g-leE3m5Bj1NmdJFJnh4Zhc6GS7SjOvSl9C0tNUQnTuqaSmnsP0yq0kDyfkHLUuLpnifBX3T8v_mE0DwWPKJ676N4Pu2uFYOMaifRA5mW0m7sp8qoReBb7-j-v-oY8xF-xeO0tOdxudv4dpElb8z48B7cyiw3u priority: 102 providerName: Elsevier |
Title | Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study |
URI | https://dx.doi.org/10.1016/j.ijid.2023.03.030 https://www.ncbi.nlm.nih.gov/pubmed/36944382 https://search.proquest.com/docview/2789711910 https://doaj.org/article/33eb5ef282464bfd968a3ee8c32a4831 |
Volume | 131 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagSAgJVVCgLI-VkbghQxI7icNtd6FqKQuC0tXeLL8ipVolqN3tkX_Cf2XGTlbLAbigRDn4kViZSeYbe-YzIS9TAYfPJUMycibgb8B04nIGttHyHFRGGJwamH8qjs_Fh2W-3NnqC2PCIj1wfHFvOPcm9zV4BqIQpnZVITX3XlqeaSF5dHzSfHCmthmRMQkOzBuryjTr02ViZFdz0SBHaMYDvSnGP--YpMDc_5tl-hPyDBbo6B7Z76EjncQh3yc3fHtAbs_7xfEDcjdOwdGYWfSA_JwHaA0wm-rWUQwip_32OrSr6bW20A-gpgvVm3anoL7UzYr2nKtXFCdr6ezz4uQdSysaYtOhUSgFwTTsbPL1jM26BcsoaHVnVwjvQ5XpMErxLZ1Q6LRigZ-VBkrbh-T86P232THrd2NgFt7mmkmtfZ5o6-AnATY_cdxIYYvS1gb8OC2MBCiTpVBdlXXitDWZq0vLjRYFL0Fej8he27X-MaGcuxKzHwx0EmUmdcqtT8BxcVq6RNcj8moQiPoeSTfUEI12oVB8CsWnEjyTEZmizLYtkTA7FIAaqV6N1L_UaETyQeKqxx4RU8Ctmr8-_MWgHgo-TFxt0a3vNlcKU4xLpM-DNodRb7ZD5EUlcAX2yf8Y-lNyBwcU49eekb315cY_B6S0NmNy8_WPdExuTaaL04_j8InA9WQ5hevpF_kLPHYSXQ |
link.rule.ids | 315,786,790,870,2115,3525,4521,27600,27955,27956,45618,45696,45907 |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGkABpQjAYlE8j8YasJrGTOLx1hamDdUh0m_pm-SsoU5VMXbv_hv-VO8edugd4QMmTfY4t3-XubN_9TMjHVMDjc8kQjJwJ0AZMJy5nYBstz0FkhMGtgelpMTkX3-b5fIeMN7kwGFYZdX-v04O2jiXDOJvDq6YZzlKwXVWZgn0LwGfyHrkvcljrYRbf_HArObLPhwNqhuQxc6YP8mouG4QLzXhAOsVQ6C3rFED87xipvzmhwRgdPSGPoxdJR_1An5Id3-6TB9N4Tr5P9vrdONonGT0jv6fBywaPm-rWUYwnp_GmHdrV9EZbaAdepwvV63aroF7qZkEj_Oo1xX1bOv5xcfyFpRUNYepAFEqBRw2bjX7O2Li7YBkFAe_sAj39UGU6DFj8TEcUGi1YgGqlAd32OTk_-no2nrB4MQOzMJsrJrX2eaKtA30B5j9x3Ehhi9LWBpZ0WhgJXk2WQnVV1onT1mSuLi03WhS8lJYfkN22a_1LQjl3JSZCGGgkykzqlFufwBrGaekSXQ_Ipw1D1FWPv6E2gWmXCtmnkH0qwTcZkEPk2S0lYmeHgm75S0XhUZx7k_sa1pqiEKZ2VSE19x6GlWkheTog-Ybj6o4owqeaf3b-YSMeCv5RPHjRre_W1wqzjUtE0gOaF73c3A6RF5XAw9hX_9nre_JwcjY9USfHp99fk0dY00eyvSG7q-XavwWfaWXehX_iD9SVERM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mortality+and+risk+factors+of+vaccinated+and+unvaccinated+frail+patients+with+COVID-19+treated+with+anti-SARS-CoV-2+monoclonal+antibodies%3A+A+real-world+study&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Nevola%2C+Riccardo&rft.au=Feola%2C+Giovanni&rft.au=Ruocco%2C+Rachele&rft.au=Russo%2C+Antonio&rft.date=2023-06-01&rft.eissn=1878-3511&rft.volume=131&rft.spage=155&rft_id=info:doi/10.1016%2Fj.ijid.2023.03.030&rft_id=info%3Apmid%2F36944382&rft.externalDocID=36944382 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon |